Journal of Advanced Research in Medicine
Volume 11, Issue 3 - 2024, Pg. No. 4-19
Peer Reviewed & Open Access Journal

Review Article

Antimicrobial Resistance in Infectious Pathogens: Diagnostic Approaches and Public Health Strategies

Carmilla Ijeoma Udensi[1], Esther Nsikak Etim[2], Sylvester Chibueze Izah[3], Prisca Chinemerem Madu[4], Akanimo Edem Asuquo[5]

[1]Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, University of Nigeria, Enugu, Enugu State, Nigeria.
[2]Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.
[3]Department of Community Medicine, Microbiology Faculty of Clinical Sciences, Bayelsa Medical University, Yenagoa, Bayelsa State, Nigeria.
[4]Global Health and Infectious Disease Institute, Nassarawa State University Keffi, Nigeria.
[5]Department of Medical Microbiology, Federal Medical Centre, Yenagoa, Bayelsa State, Nigeria.

DOI: https://doi.org/10.24321/2349.7181.202408

INFO

Corresponding Author:
Sylvester Chibueze Izah, Department of Community Medicine, Microbiology Faculty of Clinical Sciences, Bayelsa Medical University, Yenagoa, Bayelsa State, Nigeria.
E-mail Id:
chivestizah@gmail.com

How to cite this article:
Udensi C I, Etim E N, Izah S C, Prisca C M, Asuquo A E. Antimicrobial Resistance in Infectious Pathogens: Diagnostic Approaches and Public Health Strategies. J Adv Res Med 2024; 11(3): 4-19.

Date of Submission: 2024-07-01
Date of Acceptance: 2024-07-30

ABSTRACT

Antimicrobial resistance (AMR) poses a critical threat to global health, defined as the reduced effectiveness of medications in treating infections. Its significance is underscored by the substantial public health burden it creates, with implications for treatment outcomes and healthcare systems worldwide. This paper explores the mechanisms driving AMR, highlighting genetic and environmental factors that contribute to resistance, particularly in critical pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), and multidrug-resistant tuberculosis (MDR-TB). The paper found various diagnostic approaches for detecting AMR, from conventional culture-based techniques to innovative molecular diagnostics and next-generation sequencing, detailing their strengths and limitations. Effective public health strategies are crucial for combating AMR, including infection control measures, antimicrobial stewardship programs, and promoting vaccination, sanitation, and hygiene practices. Furthermore, the role of international policies, such as the WHO's Global Action Plan, is emphasized. In addition, public health education and community engagement are essential for fostering awareness and responsible antibiotic use. The paper heighted future research directions, highlighting the advances in diagnostic tools and emerging therapeutic approaches, such as phage therapy and CRISPR-based technologies. Ultimately, a One Health framework that integrates human, animal, and environmental health perspectives is vital for effectively addressing the challenges of AMR and safeguarding public health.

Keywords: Antimicrobial Resistance, Infectious Pathogens, Diagnostic Approaches, Public Health Strategies, Surveillance, One Health Framework

Journal of Advanced Research in Medicine (P-ISSN: 2394-7047 & E-ISSN: 2349-7181)

Copyright (c) 2024: Author(s). Published by Advanced Research Publications

Introduction

Antimicrobial resistance (AMR) represents one of the most pressing global health challenges of our time, with profound implications for public health, healthcare systems, and economies worldwide (Ovuru et al., 2024; Kigigha et al., 2015, 2016, 2018a,b; Izah et al., 2018a,b). The World Health Organization (WHO) has identified AMR as a critical threat, predicting that by 2050, it could lead to approximately 10 million deaths annually if current trends continue without intervention (Garau & Bassetti, 2018). This alarming statistic underscores the urgency of addressing AMR through comprehensive strategies involving antibiotic stewardship, public awareness, and enhanced surveillance systems.

The global burden of AMR is not uniformly distributed; it varies significantly between high-income countries (HICs) and low- and middle-income countries (LMICs). In LMICs, the prevalence of multidrug-resistant (MDR) infections is particularly concerning, as these regions often lack the necessary healthcare infrastructure to combat AMR effectively (Hay et al., 2018). For instance, infections that were once easily treatable with common antibiotics are becoming increasingly challenging to manage due to rising resistance levels. This situation is exacerbated by the overuse and misuse of antibiotics, frequently administered without proper medical oversight, especially in community settings (Hay et al., 2018; Dunachie et al., 2020).

The economic implications of AMR are staggering. A study estimated that the financial burden of antibiotic resistance could reach between USD 60 to 100 trillion by 2050, primarily due to increased healthcare costs and lost productivity (Siltrakool et al., 2021). This economic strain is compounded by resistant infections, often leading to more extended hospital stays, more complicated medical procedures, and higher morbidity and mortality rates (Mendelsohn et al., 2020; Gandra et al., 2014). The rising costs of treating resistant infections place additional pressure on already strained healthcare systems, particularly in countries with limited resources.

Public health implications of AMR extend beyond individual health outcomes; they involve broader societal impacts. The rise of resistant infections threatens the effectiveness of routine medical procedures, such as surgeries and chemotherapy, which rely on effective antibiotics to prevent and treat infections (Mendelsohn et al., 2020). As resistance levels increase, the risk of surgical complications and post-operative infections rises, leading to higher rates of morbidity and mortality. This situation poses a significant challenge to healthcare providers and policymakers, who must navigate the delicate balance between managing existing infections and preventing the emergence of new resistant strains.

The COVID-19 pandemic has further complicated the landscape of AMR. The pandemic has led to increased antibiotic prescribing, particularly in patients with COVID-19, despite the viral nature of the disease (Langford et al., 2021; Rodríguez-Baño et al., 2021). This trend raises concerns about the potential exacerbation of AMR, as the inappropriate use of antibiotics can accelerate the development of resistance. Additionally, disruptions to AMR surveillance programs during the pandemic have hindered efforts to monitor and control resistance patterns, making it more challenging to implement effective interventions (Rodríguez-Baño et al., 2021).

Antimicrobial stewardship (AMS) is a critical component of addressing AMR. Effective AMS programs aim to optimize the use of antimicrobials, ensuring that they are prescribed only when necessary and that the appropriate agents are selected for treatment (Netthong et al., 2022; Rolfe et al., 2021). Community pharmacists play a vital role in AMS, as they are often the first point of contact for patients seeking infection treatment. Education and awareness campaigns targeting pharmacists can enhance their ability to promote responsible antibiotic use and contribute to reducing AMR (Netthong et al., 2022).

Moreover, integrating AMS into primary healthcare settings is essential, particularly in fragile and conflict-affected regions where healthcare systems are often under-resourced (Truppa et al., 2023). Implementing AMS in these contexts can help mitigate the impact of AMR and improve health outcomes for vulnerable populations. The need for a global response to AMR is evident, and such efforts must be inclusive of all healthcare settings, ensuring that strategies are tailored to the specific challenges faced by different regions (Truppa et al., 2023).

Research and innovation are also crucial in the fight against AMR. Developing new antibiotics and alternative therapies is essential to counteract the rising tide of resistant infections (Kelbrick, 2023), especially from plants (Izah et al., 2024a,b,c; Izah & Odubo, 2023). However, the pipeline for new antibiotics is alarmingly sparse, with few novel agents being developed in recent years (Katwyk et al., 2018). This situation necessitates increased investment in research and development and incentives for pharmaceutical companies to prioritize antibiotic innovation (Kelbrick, 2023).

The purpose of this study is to analyze the mechanisms driving AMR in pathogens, focusing on genetic and environmental contributors and key resistant pathogens such as multidrug-resistant tuberculosis (MDR-TB), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant enterococci (VRE). It also aims to evaluate current diagnostic techniques and surveillance challenges while identifying gaps and limitations in AMR tracking and data-sharing practices. Furthermore, the study explores public health interventions, community education, and innovative research for controlling AMR, emphasizing collaborative approaches and future advancements in AMR prevention and management.

Mechanisms of Antimicrobial Resistance in Pathogens

Antimicrobial resistance (AMR) represents a significant global health challenge driven by a complex interplay of genetic and environmental factors. Understanding these drivers is crucial for developing effective strategies to combat AMR, particularly in critical pathogens such as MDR-TB, MRSA, and VRE. Table 1 overviews the genetic and environmental drivers of AMR and their implications.

Table 1.Genetic and Environmental Drivers of Antimicrobial Resistance

Drivers of AMR Genetic Drivers	Description	Public Health Implications
Mutation and Selection	Genetic mutations confer resistance, leading to resistant strains.	Increased treatment failures and prolonged infection duration.
Horizontal Gene Transfer	Resistance genes spread between bacteria through plasmids and transposons.	The rapid emergence of resistant infections complicates treatment.
Biofilm Formation	Increased resistance due to reduced antibiotic penetration and survival strategies.	Biofilm-associated infections are more complicated to diagnose and treat.
Antibiotic Overuse	Overprescribing and misuse contribute to resistant strain development.	Heightened risk of AMR in communities, leading to increased morbidity.
Environmental Contamination	The presence of antibiotics and resistant bacteria in the environment promotes resistance.	Increased spread of resistant bacteria, impacting public health and safety.
Environmental Drivers		
Socioeconomic Factors	Poor sanitation and healthcare access exacerbate the spread of AMR.	Disproportionate impact on vulnerable populations and health disparities.
Antibiotic Overuse	Overprescribing and misuse contribute to resistant strain development.	Increased AMR, treatment failures, and higher healthcare costs.
Environmental Contamination	The presence of antibiotics and resistant bacteria in the environment promotes resistance.	Spread of resistant pathogens, ecosystem disruption, and public health risks.
Key Pathogens		
Methicillin-resistant Staphylococcus aureus (MRSA)	A common cause of skin infections, resistant to many antibiotics.	Increased healthcare costs and burden on healthcare systems.
Vancomycin-resistant Enterococci (VRE)	Resistant to vancomycin, causing severe infections in healthcare settings.	Challenges in treating infections in immunocompromised patients.
Multidrug-Resistant Tuberculosis (MDR-TB)	Resistant to critical TB treatments, challenging to treat and control.	Greater public health risk due to transmission potential and increased mortality.

Genetic mutations in pathogens are a primary driver of AMR, as they can lead to the emergence of resistant strains through natural selection. For instance, mutations in the Mycobacterium tuberculosis genome can confer resistance to critical antibiotics such as isoniazid and rifampicin, which are the cornerstones of tuberculosis treatment (Eshetie et al., 2017). The selection pressure exerted by using these antibiotics in clinical settings often favors the survival of resistant strains, thereby exacerbating the problem of MDR-TB (Goyal et al., 2017). Moreover, the genetic diversity among M. tuberculosis strains, particularly in regions with high rates of previous treatment, has been linked to increased rates of drug resistance (Dreyer et al., 2022). This highlights the importance of understanding the genetic mechanisms underlying resistance to inform treatment strategies.

Horizontal gene transfer (HGT) is another significant genetic driver of AMR, facilitating the rapid spread of resistance genes among bacterial populations. This process can occur via plasmids, transposons, or bacteriophages, allowing for the exchange of resistance traits between different bacterial species (Sichen et al., 2023). For example, studies have shown that HGT plays a crucial role in disseminating resistance genes in both clinical and environmental settings, contributing to the emergence of resistant strains in various pathogens, including MRSA and VRE (Ramachandra, 2023). The ability of bacteria to acquire resistance genes from their environment or other bacteria underscores the need for comprehensive surveillance and control measures to limit the spread of AMR.

Biofilm formation is another genetic factor that enhances bacterial resistance to antibiotics. Bacteria within biofilms exhibit a unique phenotype characterized by altered gene expression and increased tolerance to antimicrobial agents (Becerra et al., 2019). This phenomenon is particularly relevant in chronic infections, where biofilms can form on medical devices or within host tissues, creating a protective environment that shields bacteria from the effects of antibiotics (Nwokeukwu et al., 2013). The persistence of biofilms in clinical settings poses significant challenges for treatment, as conventional antibiotic therapies often fail to penetrate these structures effectively (Abbo et al., 2011). Understanding the genetic basis of biofilm formation and its role in AMR is essential for developing targeted therapeutic strategies.

Environmental factors also play a critical role in the development and spread of AMR. One of the most significant contributors is the overuse and misuse of antibiotics in human medicine and agriculture. The inappropriate prescribing of antibiotics, often driven by patient demand and lack of awareness among healthcare providers, has increased resistance rates (Heyckendorf et al., 2020). For instance, studies have shown that many healthcare professionals acknowledge the overuse of antibiotics, yet many do not perceive it as a problem within their institutions (Abouyannis et al., 2014). This discrepancy highlights the need for improved education and awareness campaigns to promote responsible antibiotic use.

Environmental contamination with antibiotics and resistant bacteria further exacerbates the AMR crisis. Wastewater, agricultural runoff, and contaminated soil can serve as reservoirs for resistant strains, facilitating their spread into human populations (Arthur et al., 2019). For example, antibiotics in wastewater have been linked to the selection of resistant bacteria, which can then enter the food chain or human habitats, increasing the risk of infections caused by resistant strains (Mittal et al., 2020). Addressing environmental contamination is, therefore, a crucial component of any comprehensive strategy to combat AMR.

Socioeconomic factors also influence the dynamics of AMR. In many low- and middle-income countries, inadequate healthcare access, poor sanitation, and public awareness contribute to the spreading of resistant pathogens (Liebenberg et al., 2022). For instance, in regions where healthcare infrastructure is lacking, patients may not receive timely or appropriate treatment, leading to increased rates of drug resistance (Ali et al., 2019). Additionally, socioeconomic disparities can affect the availability of effective antibiotics and diagnostic tools, further complicating efforts to manage AMR (Lu et al., 2019). Addressing these socioeconomic determinants is vital for implementing effective AMR control measures. Key AMR-associated pathogens, such as MRSA, VRE, and MDR-TB, pose significant public health threats. MRSA is notorious for causing skin infections and severe illnesses, with resistance to multiple standard antibiotics complicating treatment options (Grandjean et al., 2015). The emergence of VRE in healthcare settings has also raised concerns, particularly among immunocompromised patients, where infections can lead to severe complications (Vries et al., 2017). Moreover, the global rise of MDR-TB, defined as resistance to at least isoniazid and rifampicin, presents a significant challenge for tuberculosis control efforts (Diriba et al., 2021). The increasing prevalence of MDR-TB is particularly alarming, with estimates suggesting that nearly half a million new cases arise each year, underscoring the urgent need for effective interventions (Molla et al., 2022).

AMR's genetic and environmental drivers are intricately linked, necessitating a multifaceted approach to address this issue. Strategies to combat AMR should include enhanced surveillance of resistant strains, improved antibiotic stewardship programs, and public health initiatives to raise awareness about the responsible use of antibiotics (Song et al., 2019). Additionally, research into novel therapeutic options and the development of rapid diagnostic tools are essential for improving treatment outcomes and reducing the burden of AMR (Reta et al., 2022). Collaborative efforts among healthcare providers, policymakers, and the public are crucial for tackling AMR's complex challenges effectively.

Diagnostic Approaches for Detecting AMR in Clinical and Public Health Settings

Antimicrobial resistance is a pressing global health challenge that necessitates the development of practical diagnostic approaches for its detection in clinical and public health settings. The conventional methods for detecting AMR primarily include culture-based techniques and susceptibility testing. Culture-based techniques involve isolating pathogens from clinical specimens and growing them in controlled laboratory environments. This traditional approach allows identifying specific pathogens and their resistance patterns, which is crucial for guiding appropriate treatment strategies. However, these methods can be time-consuming, often requiring several days to yield results, which can delay critical clinical decision-making (Nurjadi et al., 2021). Table 2 shows the diagnostic approaches for detecting AMR in clinical and public health settings.

Susceptibility testing complements culture-based techniques by determining the effectiveness of various antibiotics against isolated pathogens. Disk diffusion and broth microdilution are commonly employed to assess bacterial susceptibility. Disk diffusion involves placing antibiotic-impregnated disks on agar plates inoculated with the pathogen, while broth microdilution assesses antibiotics' minimum inhibitory concentration (MIC). Although these methods are considered the gold standard for AMR detection, they are limited by their reliance on viable cultures. They can miss non-culturable organisms or those in low abundance (Nurjadi et al., 2021; Boolchandani et al., 2019).

In contrast to conventional methods, molecular diagnostics have emerged as a rapid and effective means of detecting AMR. Rapid testing innovations, particularly those utilizing polymerase chain reaction (PCR) techniques, enable the swift identification of resistant strains and their genetic markers. For instance, studies have demonstrated the efficacy of PCR in detecting macrolide resistance in Streptococcus pneumoniae, showcasing its potential for timely clinical application (Nelson et al., 2019). The advantages of molecular diagnostics lie in their ability to provide results within hours, significantly reducing the time to diagnosis compared to culture-based methods. This rapid turnaround is particularly beneficial in acute care settings where prompt treatment is essential (Nelson et al., 2019; Kosai et al., 2022).

Moreover, molecular diagnostics can detect specific resistance genes, allowing for a more targeted approach to treatment. For example, the BioFire FilmArray Pneumonia Panel has been shown to enhance the detection of pathogens and antimicrobial resistance markers in lower respiratory tract specimens, outperforming traditional culture methods regarding sensitivity and specificity (Kosai et al., 2022). Such advancements underscore the importance of integrating molecular diagnostics into routine clinical practice to improve patient outcomes and combat the spread of AMR.

Metagenomics and next-generation sequencing (NGS) represent another frontier in the detection of AMR. These techniques facilitate the comprehensive analysis of microbial communities and their resistance genes directly from clinical samples without culturing. Metagenomic sequencing has been successfully applied to various clinical contexts, including orthopedic device infections, where it has demonstrated high concordance for AMR gene detection (Street et al., 2022; Abdelghany et al., 2022). The ability to analyze complex microbial ecosystems provides insights into the diversity of resistance mechanisms and aids in tracking the spread of AMR within populations and environments (Street et al., 2022; Abdelghany et al., 2022).

The benefits of metagenomics extend beyond pathogen identification; they also involve the detection of mixed infections and the characterization of resistance profiles. For instance, targeted enrichment strategies have been employed to enhance the detection of AMR genes in critically ill patients with lower respiratory tract infections, demonstrating the potential of NGS to inform clinical management (Abdelghany et al., 2022). Furthermore, the application of metagenomic sequencing in monitoring antibiotic resistance genes in wastewater treatment highlights its role in public health surveillance (Nguyen et al., 2021). This approach allows for identifying resistance trends in diverse environments, contributing to a more comprehensive understanding of AMR dynamics.

Despite the promise of molecular diagnostics and metagenomics, challenges remain in implementing these technologies in clinical settings. The complexity of data interpretation, particularly with NGS, necessitates robust bioinformatics tools and expertise to accurately analyze and report findings (Am et al., 2021). Additionally, integrating these advanced diagnostic methods into existing healthcare frameworks requires significant investment in infrastructure and training (Trick et al., 2021). Nevertheless, the potential benefits of rapid and accurate AMR detection underscore the need for continued research and development in this area.

Table 2.Diagnostic approaches for detecting antimicrobial resistance (AMR) in clinical and public health settings

Diagnostic Approach	Description	Examples	Advantages
Conventional methods	Traditional techniques to identify pathogens and test resistance.	Culture-based techniques, susceptibility testing	Established methods are reliable for many pathogens.
Molecular diagnostics	Rapid testing using genetic techniques to detect resistance.	PCR, rapid antigen tests	Quick results and timely clinical decision-making.
Metagenomics	Analyzes microbial communities and resistance genes without culturing.	Next-Generation Sequencing (NGS)	Comprehensive insights into resistance diversity.
Next-generation sequencing	High-throughput sequencing to identify pathogens and resistance genes.	Direct analysis from clinical samples	In-depth tracking of AMR spread in populations.

Challenges in AMR Diagnostics and Surveillance

The challenges associated with antimicrobial resistance (AMR) diagnostics and surveillance are multifaceted and deeply rooted in the limitations of current diagnostic methods, gaps in surveillance systems, and issues related to data-sharing and infrastructure (Figure 1). Understanding these challenges is crucial for developing effective strategies to combat AMR globally.



Limitations of current diagnostic methods for AMR

- Many conventional diagnostic techniques, such as culture-based methods, are time-consuming and may fail to identify all resistant strains.
- Variability in susceptibility testing results can lead to inconsistent treatment decisions.
- Lack of standardization in testing protocols across laboratories impacts reliability.

Surveillance gaps in tracking AMR across different regions

- Insufficient data collection and reporting mechanisms hinder the understanding of AMR trends and patterns.
- Many low- and middle-income countries lack robust surveillance systems, resulting in underreporting of AMR cases.
- Disparities in resources and infrastructure can exacerbate regional differences in AMR prevalence.

Data-sharing issues and infrastructure needs

- Limited collaboration between healthcare facilities, laboratories, and public health agencies restricts comprehensive AMR data analysis.
- Concerns over data privacy and ownership impede effective sharing of AMR-related information.
- Investment in technological infrastructure and training is necessary to enhance data collection and sharing capabilities.

Figure 1.Challenges in antimicrobial resistance diagnostics and surveillance

Current diagnostic methods for AMR, particularly culture-based techniques, are often time-consuming and can fail to identify all resistant strains. This limitation is particularly pronounced in low- and middle-income countries (LMICs), where laboratory capacity is frequently inadequate. For instance, Sandar et al. (2021) highlight that without well-equipped laboratories, it is impossible to establish a functioning AMR surveillance system. Additionally, variability in susceptibility testing results can lead to inconsistent treatment decisions, further complicating the management of infections caused by resistant pathogens (Gandra et al., 2020). The lack of standardization in testing protocols across laboratories exacerbates these issues, leading to unreliable results that can misguide clinical practices (Acharya et al., 2021).

Surveillance gaps in tracking AMR across different regions present another significant challenge. Insufficient data collection and reporting mechanisms hinder understanding AMR trends and patterns, particularly in LMICs where robust surveillance systems are often lacking. For example, Walia et al. (2019) emphasized the importance of timely detection of changes in antibiotic susceptibility to prevent further resistance development, yet many countries struggle with inadequate surveillance frameworks. This underreporting of AMR cases is compounded by disparities in resources and infrastructure, which can exacerbate regional differences in AMR prevalence (Frumence et al., 2021). The lack of comprehensive data limits the ability of public health authorities to implement effective interventions and policies to combat AMR.

Data-sharing issues further complicate the landscape of AMR diagnostics and surveillance. Limited collaboration between healthcare facilities, laboratories, and public health agencies restricts comprehensive AMR data analysis, as highlighted by Upadhaya et al. (2023), who noted the challenges in extracting data from laboratory information systems. Concerns over data privacy and ownership impede the effective sharing of AMR-related information, which is essential for a coordinated response to this global health threat (Do et al., 2023). Moreover, investment in technological infrastructure and training is necessary to enhance data collection and sharing capabilities, as Gandra et al. (2020) emphasized the need for improved financial resources and technical capacity in LMICs.

Integrating One Health approaches into AMR surveillance systems is increasingly recognized as vital for addressing the complexities of AMR. This approach emphasizes the interconnectedness of human, animal, and environmental health (Izah et al., 2024d,e,f; 2023)in understanding and combating AMR (Aenishaenslin et al., 2019). However, implementing such integrated systems faces significant challenges, including the need for collective governance and prioritization of infrastructure across various sectors (Ariyawansa et al., 2023). The lack of adequate strategies and resources in many countries, particularly in Africa, hampers the development of effective AMR surveillance programs (Katale et al., 2020).

Furthermore, the COVID-19 pandemic has introduced additional complications to AMR surveillance efforts. Hirabayashi et al. (2021) discussed how the pandemic has affected antimicrobial resistance surveillance, noting that fluctuations in healthcare utilization and antibiotic prescribing patterns can skew AMR data. This underscores the need for adaptable surveillance systems that respond to changing healthcare landscapes and maintain the integrity of AMR data collection.

Public Health Strategies to Combat Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to global public health, necessitating comprehensive public health strategies to combat its rise. One of the primary strategies involves infection control measures and antimicrobial stewardship programs. These programs aim to optimize the use of antibiotics, thereby reducing unnecessary prescriptions and the subsequent development of resistant strains of bacteria. Evidence suggests that variability in antibiotic use across healthcare settings can lead to both undertreatment and overtreatment of infections, which emphasizes the need for effective stewardship programs, particularly in pediatric hospitals where the potential for improvement is substantial (Gerber et al., 2010; Newland et al., 2014). By establishing strict protocols for infection control, healthcare facilities can significantly mitigate the spread of infections, which is crucial in reducing the reliance on antibiotics and, consequently, the emergence of AMR (Viale et al., 2015; Fishman, 2012). Figure 2 shows the public health strategies to combat Antimicrobial resistance

In addition to stewardship programs, regular training and education for healthcare professionals on AMR and appropriate prescribing practices are essential to a robust public health strategy. Continuous professional development ensures that healthcare providers remain informed about the latest guidelines and best practices in antibiotic prescribing. Studies have shown that well-educated healthcare professionals about AMR are more likely to adhere to policies, thus minimizing the risk of inappropriate antibiotic use (Fishman, 2012). Furthermore, integrating AMR education into medical curricula can foster a culture of responsible antibiotic use among future healthcare providers, ultimately leading to better patient outcomes and reduced resistance rates (Slayton et al., 2015).

Vaccination, sanitation, and hygiene are crucial in preventing infections that could lead to antibiotic use. Enhanced



Infection control measures and stewardship programs

- Implementing strict protocols to prevent the spread of infections in healthcare settings.
- Promoting antimicrobial stewardship to optimize the use of antibiotics and reduce unnecessary prescriptions.
- Regular training and education for healthcare professionals on AMR and appropriate prescribing practices.

Role of Vaccination, Sanitation, and Hygiene in AMR prevention

- Enhancing vaccination programs to prevent infections that could lead to antibiotic use.
- Promoting sanitation practices, including clean water access and waste management, to reduce pathogen transmission.
- Encouraging personal and community hygiene practices, such as handwashing, to lower infection rates.

International policies and collaborative frameworks

- Supporting the implementation of WHO's Global Action Plan on AMR to foster global cooperation in addressing AMR challenges.
- Establishing regional and national policies to facilitate collaboration among countries, public health organizations, and stakeholders.
- Promoting data sharing and research initiatives to strengthen AMR surveillance and response strategies globally.

Figure 2.Public health strategies to combat antimicrobial resistance

vaccination programs can significantly reduce the incidence of vaccine-preventable diseases, thereby decreasing the need for antibiotics. For instance, implementing widespread vaccination against pathogens such as Streptococcus pneumoniae has lowered the prevalence of infections contributing to AMR (Spika & Rud, 2015). Promoting sanitation practices, including access to clean water and effective waste management, is vital in reducing pathogen transmission within communities. Poor sanitation is a known risk factor for the spread of infectious diseases, which can lead to increased antibiotic use and resistance (Spika & Rud, 2015). Encouraging personal and community hygiene practices, such as regular handwashing, further lowers infection rates and, by extension, the demand for antibiotics (Valencia et al., 2016).

International policies and collaborative frameworks are critical in addressing the global challenge of AMR. The World Health Organization's Global Action Plan on AMR is a framework for countries to foster cooperation in combating AMR challenges (Viale et al., 2015). By establishing regional and national policies that facilitate collaboration among governments, public health organizations, and stakeholders, a more coordinated response to AMR can be achieved. This collaboration is essential for sharing global data and research initiatives that strengthen AMR surveillance and response strategies (Slayton et al., 2015). Countries actively participating in international efforts to combat AMR can benefit from shared knowledge and resources, ultimately leading to more effective public health interventions.

Data sharing and research initiatives are vital for enhancing AMR surveillance and response strategies. By promoting transparency and collaboration among healthcare institutions, public health agencies can better understand the patterns of antibiotic resistance and the factors contributing to its rise. Research initiatives focusing on the epidemiology of AMR can inform targeted interventions and policies, ensuring that resources are allocated effectively to combat the most pressing threats (Viale et al., 2015; Slayton et al., 2015). Furthermore, establishing a global database on antibiotic use and resistance patterns can facilitate real-time monitoring and response to emerging resistance trends, allowing for timely public health interventions (Viale et al., 2015).

The role of antimicrobial stewardship programs (ASPs) cannot be overstated in the fight against AMR. ASPs are designed to optimize the use of antimicrobials, ensuring that patients receive the most appropriate therapy while minimizing the risk of resistance development (Fishman, 2012; Slayton et al., 2015). Evidence indicates that hospitals with established ASPs are more likely to monitor antimicrobial use and outcomes, leading to improved prescribing practices and reduced rates of resistance (Newland et al., 2014; Viale et al., 2015). Moreover, ASPs can help educate healthcare providers about the importance of judicious antibiotic use, fostering a culture of accountability and responsibility within healthcare settings (Fishman, 2012; Slayton et al., 2015).

In long-term care facilities, the implementation of antimicrobial stewardship is equally crucial. These settings are often at higher risk for the emergence of resistant organisms due to the vulnerable populations they serve and the frequent use of antibiotics (Morrill et al., 2016). A call to action has been made to establish ASPs in long-term care facilities to address the unique challenges they face in managing infections and preventing AMR (Morrill et al., 2016). By tailoring stewardship efforts to the specific needs of these facilities, public health officials can enhance the effectiveness of interventions aimed at reducing antibiotic use and resistance.

Integrating vaccination programs into public health strategies is a powerful tool in the fight against AMR. Vaccination prevents infections and reduces the need for antibiotics, thereby decreasing the selective pressure that drives resistance (Spika & Rud, 2015). For instance, vaccines targeting pathogens such as Clostridium difficile and Neisseria gonorrhoeae are in development and hold promise for reducing the burden of infections that contribute to AMR (Spika & Rud, 2015). Furthermore, historical data demonstrates that vaccination campaigns have significantly reduced infectious disease incidence and mortality, underscoring the importance of immunization in public health efforts (Mokhort et al., 2018).

Role of Public Education and Community Engagement in AMR Prevention

Public education and community engagement in combating antimicrobial resistance (AMR) is increasingly recognized as a critical component of public health strategies. Awareness campaigns and educational initiatives foster a well-informed public that can actively participate in AMR prevention. For instance, evidence suggests that inappropriate use of antimicrobials is prevalent in various settings, including hospitals and community environments, necessitating targeted educational interventions (Kamere et al., 2022). Campaigns aimed at raising awareness about AMR can significantly influence public understanding; however, their effectiveness often hinges on the depth and breadth of the educational content provided. A UK-wide campaign highlighted that while awareness increased, the impact on knowledge and behavior change was limited, suggesting that multifaceted approaches are necessary for meaningful engagement (Chaintarli et al., 2016).

Healthcare providers play a crucial role in AMR prevention, and strategies to engage them must be robust and comprehensive. Educational programs tailored for healthcare professionals have improved antimicrobial prescribing practices, thereby contributing to better stewardship (Chaintarli et al., 2016). However, the effectiveness of these programs can be undermined by a lack of coordinated action among healthcare institutions and regulatory bodies (Broom et al., 2021). In many low- and middle-income countries, the absence of cohesive policies and the limited involvement of professional associations in AMR initiatives further complicate the landscape (Broom et al., 2021). Therefore, fostering a collaborative environment where healthcare providers are educated and actively involved in AMR prevention strategies is essential for achieving sustainable outcomes.

Community engagement is equally vital in the fight against AMR, as public understanding of the issue directly influences behavior and health outcomes. Research indicates that many individuals lack a clear understanding of AMR, with misconceptions prevalent among the general public (Onah & Umar, 2023). For instance, a survey in Nigeria revealed that only 8.3% of respondents had a good grasp of AMR concepts, emphasizing the need for targeted educational efforts (Onah & Umar, 2023). Engaging the community through interactive platforms, such as social media and academic theatre, can enhance public interest and understanding of AMR (Maugeri et al., 2022; Ahmed et al., 2020). These innovative approaches disseminate information and create a dialogue around AMR, empowering individuals to take responsibility for their health and antibiotic use.

The integration of health literacy into AMR education is crucial for fostering informed decision-making among the public. Enhancing health literacy enables individuals to comprehend health information, follow guidelines, and engage in preventive behaviors (Castro-Sánchez et al., 2016). Studies have shown that individuals with higher health literacy are more likely to adopt recommended practices, such as proper antibiotic use and adherence to treatment protocols (Castro-Sánchez et al., 2016). Therefore, educational initiatives must prioritize clear communication and accessible information to ensure that all community members can participate effectively in AMR prevention efforts. This approach aligns with findings that public engagement can synergistically affect other interventions targeting prescribers and healthcare systems (McParland et al., 2018).

Moreover, global events such as the COVID-19 pandemic's impact on public interest in AMR cannot be overlooked. The pandemic has altered public perceptions and behaviors related to health, including antibiotic use (Maugeri et al., 2022). As such, it is imperative to develop new campaigns that address the challenges posed by the pandemic while reinforcing the importance of responsible antimicrobial use. Interactive websites and social media campaigns have emerged as practical tools for raising awareness and educating the public about AMR during this period (Maugeri et al., 2022). These platforms allow for real-time engagement and feedback, fostering a sense of community involvement in the fight against AMR.

Future Research and Technological Innovations in AMR Control

The emergence of antimicrobial resistance has become a pressing global health challenge, necessitating innovative approaches to diagnosis, treatment, and prevention. Future research in AMR control increasingly focuses on advanced diagnostic tools that can rapidly identify resistant pathogens. For instance, CRISPR-based technologies have shown promise in enhancing the detection of AMR genes, allowing for quicker and more accurate identification of resistant strains compared to traditional methods like polymerase chain reaction (PCR) (Adefisoye & Olaniran, 2023; Wu et al., 2021). These diagnostics advancements facilitate timely treatment decisions and better surveillance of AMR trends, which is crucial for public health interventions (Leclerc et al., 2019; Likotrafiti et al., 2018). Moreover, the integration of whole genome sequencing (WGS) and metagenomic approaches can provide comprehensive insights into the dynamics of AMR gene transmission across various environments, including clinical settings and the food chain (Likotrafiti et al., 2018).

In parallel with advancements in diagnostics, emerging treatments and alternative therapies are gaining traction as potential solutions to combat AMR. Phage therapy, which utilizes bacteriophages to target and kill specific bacterial pathogens, has been highlighted as a viable alternative to traditional antibiotics (Huang et al., 2022). Recent studies have demonstrated the effectiveness of engineered phages tailored to enhance their lytic activity against resistant strains, thereby minimizing the risk of resistance development (Bhargava et al., 2021; Federici et al., 2022). Additionally, the combination of phage therapy with CRISPR-Cas systems has shown potential in selectively targeting and eliminating AMR determinants from bacterial populations, thereby reducing the spread of resistance (Parsons et al., 2021; Kiga et al., 2020). This synergistic approach addresses the immediate threat posed by resistant pathogens and contributes to the long-term sustainability of antimicrobial strategies by mitigating the horizontal gene transfer of resistance traits (Botelho et al., 2022).

The One Health approach recognizes the interconnectedness of human, animal, and environmental health and is critical in the fight against AMR. This holistic perspective emphasizes the need for collaborative efforts across various sectors to monitor and control the spread of resistant pathogens (Huang et al., 2022). Research has shown that AMR can be exacerbated by factors such as agricultural practices, environmental contamination, and zoonotic transmission, underscoring the importance of integrated surveillance systems that involve all aspects of health (Likotrafiti et al., 2018; Huang et al., 2022). By fostering interdisciplinary collaboration, stakeholders can develop comprehensive strategies that address the root causes of AMR and promote responsible antibiotic use across different domains, including healthcare, agriculture, and environmental management (Tagliaferri et al., 2020).

Moreover, the development of CRISPR-based antimicrobials represents a significant advancement in the arsenal against AMR. These innovative tools leverage the precision of CRISPR technology to target and disrupt the genetic elements responsible for antibiotic resistance in bacteria (Ahmed et al., 2023). For example, CRISPR-Cas systems have been engineered to specifically cleave plasmids that carry resistance genes, effectively removing them from bacterial populations (Junaid et al., 2023; Walker-Sünderhauf et al., 2023). This targeted approach enhances the efficacy of treatment and reduces the likelihood of resistance re-emerging, as it directly addresses the genetic basis of AMR (Wongpayak et al., 2021). Furthermore, the versatility of CRISPR technology allows for the development of multiplexed systems capable of targeting multiple resistance genes simultaneously, thereby broadening the scope of intervention strategies (Uribe et al., 2021).

Conclusion

The significance of AMR is profound, presenting a multifaceted threat to global health that extends beyond individual infections to economic, societal, and healthcare system challenges. Genetic and environmental factors interplay is critical in developing and spreading AMR, particularly among key pathogens such as MRSA, VRE, and MDR-TB. Addressing these underlying drivers is essential for formulating effective strategies to combat AMR. A comprehensive approach that includes enhanced surveillance, responsible antibiotic use, public education, and investment in research and development is vital for mitigating the impact of AMR and preserving the efficacy of antibiotics for future generations.

A multifaceted strategy is necessary to combat AMR, involving strict infection control measures, antimicrobial stewardship, vaccination programs, and international collaboration. Implementing advanced diagnostic tools and innovative therapeutic approaches, such as CRISPR technology and phage therapy, can significantly enhance our ability to address resistant pathogens. Additionally, fostering public education and community engagement through awareness campaigns will cultivate a culture of responsibility surrounding antibiotic use. By leveraging a One Health framework that integrates human, animal, and environmental health perspectives, we can develop sustainable and practical strategies to combat the growing threat of AMR and safeguard public health.

References

1. Abbo L, Sinkowitz-Cochran R, Smith L, Ariza-Heredia E, Gómez-Marín O, Srinivasan A, Hooton TM. Faculty and resident physicians' attitudes, perceptions, and knowledge about antimicrobial use and resistance. Infect Control Hosp Epidemiol. 2011;32(7):714-718. https://doi.org/10.1086/660761
2. Abouyannis M, Dacombe R, Dambe I, Mpunga J, Faragher B, Gausi F, Ndhlovu H, Kachiza C, Suarez P, Mundy

C, et al. Drug resistance of mycobacterium tuberculosis in Malawi: a cross-sectional survey. Bull World Health Organ. 2014;92(11):798-806. https://doi.org/10.2471/blt.13.126532

3. Acharya J, Zolfo M, Enbiale W, Kyaw KWY, Bhattachan M, Rijal N, Shrestha A, Shrestha B, Madhup SK, Raghubanshi BR, et al. Quality assessment of an antimicrobial resistance surveillance system in a province of Nepal. Trop Med Infect Dis. 2021;6(2):60. https://doi.org/10.3390/tropicalmed6020060
4. Adefisoye MA, Olaniran AO. Antimicrobial resistance expansion in pathogens: a review of current mitigation strategies and advances towards innovative therapy. JAC-Antimicrob Resist. 2023;5(6). https://doi.org/10.1093/jacamr/dlad127
5. Aenishaenslin C, Häsler B, Ravel A, Parmley J, Stärk K, Buckeridge D. Evidence needed for antimicrobial resistance surveillance systems. Bull World Health Organ. 2019;97(4):283-289. https://doi.org/10.2471/blt.18.218917
6. Ahmed R, Bashir A, Brown JE, Cox JA, Hilton AC, Jordan SL, Theodosiou E, Worthington T. Aston University's antimicrobial resistance (AMR) roadshow: raising awareness and embedding knowledge of AMR in key stage 4 learners. Infect Prev Pract. 2020;2(2):100060. https://doi.org/10.1016/j.infpip.2020.100060
7. Ahmed S, Ahmed MZ, Rafique S, Almasoudi SE, Shah M, Jalil NAC, Ojha SC. Recent approaches for downplaying antibiotic resistance: molecular mechanisms. Biomed Res Int. 2023;2023(1). https://doi.org/10.1155/2023/5250040
8. Ali MH, Alrasheedy AA, Hassali MA, Kibuule D, Godman B. Predictors of multidrug-resistant tuberculosis (MDR-TB) in Sudan. Antibiotics. 2019;8(3):90. https://doi.org/10.3390/antibiotics8030090
9. Ariyawansa S, Gunawardana KN, Hapudeniya MM, Manelgamage NJ, Karunarathne CR, Madalagama RP, Ubeyratne KH, Wickramasinghe D, Tun HM, Wu P, et al. One Health surveillance of antimicrobial use and resistance: challenges and successes of implementing surveillance programs in Sri Lanka. Antibiotics. 2023;12(3):446. https://doi.org/10.3390/antibiotics12030446
10. Arthur PK, Amarh V, Cramer P, Arkaifie GB, Blessie EJ, Fuseini MS, Carilo I, Yeboah R, Asare L, Robertson BD. Characterization of two new multidrug-resistant strains of mycobacterium smegmatis: tools for routine in vitro screening of novel anti-mycobacterial agents. Antibiotics. 2019;8(1):4. https://doi.org/10.3390/antibiotics8010004
11. Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, et al. Transmissibility and potential for disease progression of drug-resistant mycobacterium tuberculosis: prospective cohort study. BMJ. 2019; l5894. https://doi.org/10.1136/bmj.l5894
12. Bhargava K, Nath G, Bhargava A, Aseri GK, Jain N. Phage therapeutics: from promises to practices and prospectives. Appl Microbiol Biotechnol. 2021;105(24):9047-9067. https://doi.org/10.1007/s00253-021-11695-z
13. Boolchandani M, D'Souza AW, Dantas G. Sequencing-based methods and resources to study antimicrobial resistance. Nat Rev Genet. 2019. https://doi.org/10.1038/s41576-019-0108-4
14. Botelho J, Cazares A, Schulenburg H. The ESKAPE mobilome contributes to the spread of antimicrobial resistance and CRISPR-mediated conflict between mobile genetic elements. Nucleic Acids Res. 2023;51(1):236-252. https://doi.org/10.1101/2022.01.03.474784
15. Broom J, Broom A, Kenny K, Post JJ, Konecny P. Institutional governance and responsiveness to antimicrobial resistance: a qualitative study of Australian hospital executives. BMJ Open. 2021;11(12). https://doi.org/10.1136/bmjopen-2021-055215
16. Castro-Sánchez E, Chang PW, Vila-Candel R, Escobedo AA, Holmes AH. Health literacy and infectious diseases: why does it matter? Int J Infect Dis. 2016;43:103-110. https://doi.org/10.1016/j.ijid.2015.12.019
17. Chaintarli K, Ingle SM, Bhattacharya A, Ashiru-Oredope D, Oliver I, Gobin M. Impact of a United Kingdom-wide campaign to tackle antimicrobial resistance on self-reported knowledge and behaviour change. BMC Public Health. 2016;16:1-9. https://doi.org/10.1186/s12889-016-3057-2
18. De Vries G, Tsolova S, Anderson LF, Gebhard AC, Heldal E, Hollo V, et al. Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences. BMC Public Health. 2017;17(1). https://doi.org/10.1186/s12889-017-4216-9
19. Diriba G, Tola HH, Alemu A, Yenew B, Gamtesa DF, Kebede A. Drug resistance and its risk factors among extrapulmonary tuberculosis in Ethiopia: a systematic review and meta-analysis. PLoS One. 2021;16(10). https://doi.org/10.1371/journal.pone.0258295
20. Do PC, Assefa YA, Batikawai SM, Reid SA. Strengthening antimicrobial resistance surveillance systems: a scoping review. BMC Infect Dis. 2023;23(1). https://doi.org/10.1186/s12879-023-08585-2
21. Dreyer V, Mandal A, Dev P, Merker M, Barilar I, Utpatel C, Nilgiriwala K, Rodrigues C, Crook DW, et al. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai metropolitan region. Genome Med. 2022;14(1). https://doi.org/10.1186/s13073-022-01076-0

22. Dunachie SJ, Day NP, Dolecek C. The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. Curr Opin Microbiol. 2020;57:95-101. https://doi.org/10.1016/j.mib.2020.09.013
23. Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, Tessema B, Moges F. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1). https://doi.org/10.1186/s12879-017-2323-y
24. Federici S, Kredo-Russo S, Valdés-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, Silberberg Y, Atarashi K, Furuichi M, Oka A, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022;185(16):2879-2898.e24. https://doi.org/10.1016/j.cell.2022.07.003
25. Fishman N. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33(4):322-327. https://doi.org/10.1086/665010
26. Frumence G, Mboera LE, Sindato C, Katale BZ, Kimera S, Metta E, Durrance-Bagale A, Jung AS, Mshana SE, Clark TG, et al. The governance and implementation of the national action plan on antimicrobial resistance in Tanzania: a qualitative study. Antibiotics. 2021;10(3):273. https://doi.org/10.3390/antibiotics10030273
27. Gandra S, Alvarez-Uria G, Turner P, Joshi J, Limmathurotsakul D, van Doorn HR. Antimicrobial resistance surveillance in low- and middle-income countries: progress and challenges in eight South Asian and Southeast Asian countries. Clin Microbiol Rev. 2020;33(3). https://doi.org/10.1128/cmr.00048-19
28. Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014;20(10):973-980. https://doi.org/10.1111/1469-0691.12798
29. Garau J, Bassetti M. Role of pharmacists in antimicrobial stewardship programmes. Int J Clin Pharm. 2018;40(5):948-952. https://doi.org/10.1007/s11096-018-0675-z
30. Gerber JS, Newland JG, Coffin SE, Hall M, Thurm C, Prasad PA, Feudtner C, Zaoutis TE. Variability in antibiotic use at children's hospitals. Pediatrics. 2010;126(6):1067-1073. https://doi.org/10.1542/peds.2010-1275
31. Goyal V, Kadam V, Narang P, Singh V. Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis. BMC Public Health. 2017;17(1):1-21. https://doi.org/10.1186/s12889-017-4779-5
32. Grandjean L, Gilman RH, Martin L, Soto E, Castro B, Lopez S, Coronel J, Castillo E, Alarcon V, Lopez V, et al. Transmission of multidrug-resistant and drug-susceptible tuberculosis within households: a prospective cohort study. PLoS Med. 2015;12(6). https://doi.org/10.1371/journal.pmed.1001843
33. Hay SI, Rao PC, Dolecek C, Day NP, Stergachis A, Lopez AD, Murray CJ. Measuring and mapping the global burden of antimicrobial resistance. BMC Med. 2018;16(1). https://doi.org/10.1186/s12916-018-1073-z
34. Heyckendorf J, Marwitz S, Reimann M, Avsar K, DiNardo A, Günther G, Hoelscher M, Ibraim E, Kalsdorf B, Kaufmann SH, et al. A 22-gene transcriptomic model indicating individual therapy durations in multidrug-resistant tuberculosis. medRxiv. 2020-08. https://doi.org/10.1101/2020.08.21.20177238
35. Hirabayashi A, Kajihara T, Yahara K, Shibayama K, Sugai M. Impact of the COVID-19 pandemic on the surveillance of antimicrobial resistance. J Hosp Infect. 2021;117:147-156. https://doi.org/10.1016/j.jhin.2021.09.011
36. Huang Y, Wang W, Zhang Z, Gu Y, Huang A, Wang J, Hao H. Phage products for fighting antimicrobial resistance. Microorganisms. 2022;10(7):1324. https://doi.org/10.3390/microorganisms10071324
37. Izah SC, Joshua MT, Torru KE, Ngun CT, Ogwu MC, Hait M. Antimicrobial resistance and the role of herbal medicine: challenges, opportunities, and future prospects. In: Izah SC, Ogwu MC, Akram M, editors. Herbal Medicine Phytochemistry. Cham: Springer; 2024a. p. 2127-2152. https://doi.org/10.1007/978-3-031-21973-3_71-1
38. Izah SC, Odubo TC, Ngun CT, Ogwu MC. Research needs of medicinal plants used in the management and treatment of some diseases caused by microorganisms. In: Izah SC, Ogwu MC, Akram M, editors. Herbal Medicine Phytochemistry. Cham: Springer; 2024b. p. 1797-1823. https://doi.org/10.1007/978-3-031-21973-3_11-1
39. Izah SC, Richard G, Odubo TC. Citrus aurantifolia: Phytochemical constituents, food preservative potentials, and pharmacological values. In: Izah SC, Ogwu MC, Akram M, editors. Herbal Medicine Phytochemistry. Cham: Springer; 2024c. p. 333-358. https://doi.org/10.1007/978-3-031-43199-9_76
40. Izah SC, Richard G, Stanley HO, Sawyer WE, Ogwu MC, Uwaeme OR. Potential Applications of Linear Regression Models in Studying the Relationship Between Fish and Contaminants in their Environment: One Health Perspective. Juniper Online Journal of Public Health. 2024d;8(4):555743. DOI: 10.19080/JOJPH.2024.08.555743.

41. Izah SC, Richard G, Stanley HO, Sawyer WE, Ogwu MC, Uwaeme OR. Prospects and Application of Multivariate and Reliability Analyses to One Health Risk Assessments of Toxic Elements. Toxicol Environ Health Sci. 2024e;16(2):127–134.
42. Izah SC, Ogwu MC, Etim NG, Shahsavani A, Namvar Z. Short-Term Health Effects of Air Pollution. In: Izah SC, Ogwu MC, Shahsavani A, editors. Air Pollutants in the Context of One Health: Fundamentals, Sources and Impacts. The Handbook in Environmental Chemistry. Springer, Berlin, Heidelberg; 2024f.
43. Izah SC, Odubo TC. Effects of Citrus aurantifolia Fruit Juice on Selected Pathogens of Public Health Importance. ES Food Agrofor. 2023;11:829. https://dx.doi.org/10.30919/esfaf829
44. Izah SC, Richard G, Stanley HO, Sawyer WE, Ogwu MC, Uwaeme OR. Integrating the One Health Approach and Statistical Analysis for Sustainable Aquatic Ecosystem Management and Trace Metal Contamination Mitigation. ES Food & Agroforestry. 2023;14:1012. DOI:10.30919/esfaf1012.
45. Izah SC, Uhunmwangho EJ, Dunga KE, Kigigha LT. Synergy of methanolic leaf and stem-bark extract of Anacardium occidentale L. (cashew) against some enteric and superficial bacterial pathogens. MOJ Toxicol. 2018a;4(3):209-211.
46. Izah SC, Uhunmwangho EJ, Dunga KE. Studies on the synergistic effectiveness of methanolic extract of leaves and roots of Carica papaya L. (papaya) against some bacterial pathogens. Int J Complement Alt Med. 2018b;11(6):375-378.
47. Izah SC, Uhunmwangho EJ, Eledo BO. Medicinal potentials of Buchholzia coriacea (wonderful kola). Med Plant Res. 2018c;8(5):27-43.
48. Junaid M, Thirapanmethee K, Khuntayaporn P, Chomnawang MT. CRISPR-based gene editing in Acinetobacter baumannii to combat antimicrobial resistance. Pharmaceuticals. 2023;16(7):920. https://doi.org/10.3390/ph16070920
49. Kamere N, Garwe ST, Akinwotu OO, Tuck C, Krockow EM, Yadav S, Olawale AG, Diyaolu AH, Munkombwe D, Muringu E, et al. Scoping review of national antimicrobial stewardship activities in eight African countries and adaptable recommendations. Antibiotics. 2022;11(9):1149. https://doi.org/10.3390/antibiotics11091149
50. Katale BZ, Misinzo G, Mshana SE, Chiyangi H, Campino S, Clark TG, Good L, Rweyemamu MM, Matee MI. Genetic diversity and risk factors for the transmission of antimicrobial resistance across human, animal, and environmental compartments in East Africa: a review. Antimicrobial Resistance and Infection Control. 2020;9(1). https://doi.org/10.1186/s13756-020-00786-7
51. Kelbrick M. Cultivating antimicrobial resistance: how intensive agriculture ploughs the way for antibiotic resistance. Microbiology. 2023;169(8). https://doi.org/10.1099/mic.0.001384
52. Kiga K, Tan XE, Ibarra-Chávez R, Watanabe S, Aiba Y, Sato'o Y, Li FY, Sasahara T, Cui B, Kawauchi M, et al. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nature Communications. 2020;11(1). https://doi.org/10.1038/s41467-020-16731-6
53. Kigigha LT, Biye SE, Izah SC. Phytochemical and antibacterial activities of Musanga cecropioides tissues against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Proteus, and Bacillus species. Int J Appl Res Technol. 2016;5(1):100-107.
54. Kigigha LT, Izah SC, Ehizibue M. Activities of Aframomum melegueta seed against Escherichia coli, Staphylococcus aureus, and Bacillus species. Point J Bot Microbiol Res. 2015;1(2):23-29.
55. Kigigha LT, Izah SC, Uhunmwangho EJ. Assessment of hot water and ethanolic leaf extracts of Cymbopogon citratus Stapf (Lemongrass) against selected bacterial pathogens. Ann Microbiol Infect Dis. 2018a;1(3):1-5.
56. Kigigha LT, Selekere RE, Izah SC. Antibacterial and synergistic efficacy of acetone extracts of Garcinia kola (Bitter kola) and Buchholzia coriacea (Wonderful kola). J Basic Pharm Toxicol. 2018b;2(1):13-17.
57. Kosai K, Akamatsu N, Ota K, Mitsumoto-Kaseida F, Sakamoto K, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K. BioFire FilmArray Pneumonia Panel enhances detection of pathogens and antimicrobial resistance in lower respiratory tract specimens. Annals of Clinical Microbiology and Antimicrobials. 2022;21(1). https://doi.org/10.1186/s12941-022-00512-8
58. Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, Daneman N, MacFadden DR. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520-531. https://doi.org/10.1016/j.cmi.2020.12.018
59. Leclerc QJ, Lindsay JA, Knight GM. Mathematical modelling to study the horizontal transfer of antimicrobial resistance genes in bacteria: current state of the field and recommendations. J R Soc Interface. 2019;16(157):20190260. https://doi.org/10.1098/rsif.2019.0260
60. Liebenberg D, Gordhan BG, Kana BD. Drug-resistant tuberculosis: implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol. 2022;12. https://doi.org/10.3389/fcimb.2022.943545
61. Likotrafiti E, Oniciuc EA, Prieto M, Santos JA, López S, Alvarez-Ordóñez A. Risk assessment of antimicrobial resistance along the food chain through culture-inde-

pendent methodologies. EFSA J. 2018;16. https://doi.org/10.2903/j.efsa.2018.e160811

62. Lu Z, Jiang W, Zhang J, Lynn HS, Chen Y, Zhang S, Ma Z, Geng P, Guo X, Zhang H, Zhang Z. Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China. PLoS One. 2019;14(11). https://doi.org/10.1371/journal.pone.0225361
63. Maugeri A, Barchitta M, Basile G, Agodi A. How COVID-19 has influenced public interest in antimicrobials, antimicrobial resistance, and related preventive measures: a Google Trends analysis of Italian data. Antibiotics. 2022;11(3):379. https://doi.org/10.3390/antibiotics11030379
64. McParland JL, Williams L, Gozdzielewska L, Young M, Smith F, MacDonald J, Langdridge D, Davis M, Price L, Flowers P. What are the 'active ingredients' of interventions targeting the public's engagement with antimicrobial resistance and how might they work? Br J Health Psychol. 2018;23(4):804-819. https://doi.org/10.1111/bjhp.12317
65. Mendelsohn E, Ross N, White AM, Whiting K, Basaraba C, Madubuonwu BW, Johnson E, Dualeh M, Matson Z, Dattaray S, et al. Extracting novel antimicrobial emergence events from scientific literature and medical reports. F1000Res. 2020;9:1320. https://doi.org/10.12688/f1000research.26870.1
66. Mittal AK, Bhardwaj R, Mishra P, Rajput SK. Antimicrobials misuse/overuse: adverse effect, mechanism, challenges and strategies to combat resistance. Open Biotechnol J. 2020;14(1):107-112. https://doi.org/10.2174/1874070702014010107
67. Mokhort H, Ковальчук A, Sokolovska O, Higgs S. Contribution of vaccination to the reduction of infectious mortality in Ukraine in the second half of the 20th and early 21st century: a comparative population-based study of the dynamics and structure of infectious mortality and incidence. Viral Immunol. 2018;31(10):695-707. https://doi.org/10.1089/vim.2018.0054
68. Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East Africa: a systematic review and meta-analysis. PLoS One. 2022;17(6). https://doi.org/10.1371/journal.pone.0270272
69. Morrill HJ, Caffrey AR, Jump RL, Dosa D, LaPlante KL. Antimicrobial stewardship in long-term care facilities: a call to action. J Am Med Dir Assoc. 2016;17(2):183.e1-183.e16. https://doi.org/10.1016/j.jamda.2015.11.013
70. Nelson MM, Waldron CL, Bracht JR. Rapid molecular detection of macrolide resistance. BMC Infect Dis. 2019;19(1). https://doi.org/10.1186/s12879-019-3762-4
71. Netthong R, Kane R, Ahmadi K. Antimicrobial resistance and community pharmacists' perspective in Thailand: a mixed methods survey using appreciative inquiry theory. Antibiotics. 2022;11(2):161. https://doi.org/10.3390/antibiotics11020161
72. Newland JG, Gerber JS, Weissman SJ, Shah SS, Turgeon C, Hedican EB, Thurm C, Hall M, Courter J, Brogan TV, et al. Prevalence and characteristics of antimicrobial stewardship programs at freestanding children's hospitals in the United States. Infect Control Hosp Epidemiol. 2014;35(3):265-271. https://doi.org/10.1086/675277
73. Nguyen AQ, Vu HP, Nguyen LN, Wang Q, Djordjevic SP, Donner E, Yin H, Nghiem LD. Monitoring antibiotic resistance genes in wastewater treatment: current strategies and future challenges. Sci Total Environ. 2021;783:146964. https://doi.org/10.1016/j.scitotenv.2021.146964
74. Nurjadi D, Zizmann E, Chanthalangsy Q, Heeg K, Boutin S. Integrative analysis of whole genome sequencing and phenotypic resistance toward prediction of trimethoprim-sulfamethoxazole resistance in Staphylococcus aureus. Front Microbiol. 2021;11. https://doi.org/10.3389/fmicb.2020.607842
75. Nwokeukwu HI, Okafor PN, Okorie O, Ukpabi IK. Paediatric multidrug-resistant tuberculosis with HIV coinfection: a case report. Case Rep Med. 2013;2013:1-3. https://doi.org/10.1155/2013/756152
76. Onah SI, Umar HJ. Appraising Nigeria's approach to combating antimicrobial resistance. Int J Health Plann Manage. 2023;39(2):556-562. https://doi.org/10.1002/hpm.3717
77. Ovuru KF, Izah SC, Yasmin H, Enerijiofi KE, Das M, Ogwu MC. Microbial contaminants of herbal remedies: health risks and sustainable quality control strategies. In: Izah SC, Ogwu MC, Akram M, editors. Herbal Medicine Phytochemistry. Cham: Springer; 2024. p. 1571-1600. https://doi.org/10.1007/978-3-031-21973-3_9-1
78. Parsons C, Brown P, Kathariou S. Use of bacteriophage amended with CRISPR-Cas systems to combat antimicrobial resistance in the bacterial foodborne pathogen Listeria monocytogenes. Antibiotics. 2021;10(3):308. https://doi.org/10.3390/antibiotics10030308
79. Ramachandra V, Brammacharry U, Muralidhar A, Muthukumar A, Mani R, Muthaiah M, Soundappan G, Frederick A. Assess the diagnostic accuracy of GeneXpert to detect Mycobacterium tuberculosis and rifampicin-resistant tuberculosis among presumptive tuberculosis and presumptive drug-resistant tuberculosis patients. Microbiol Res. 2023;15(1):91-108.
80. Reta MA, Tamene BA, Abate BB, Mensah E, Maningi NE, Fourie PB. Mycobacterium tuberculosis drug resistance in Ethiopia: an updated systematic review and meta-analysis. Trop Med Infect Dis. 2022;7(10):300. https://doi.org/10.3390/tropicalmed7100300
81. Rodríguez-Baño J, Rossolini GM, Schultsz C, Tacconelli E, Murthy S, Ohmagari N, Holmes A, Bachmann T,

Goossens H, Canton R, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Trans R Soc Trop Med Hyg. 2021;115(10):1122-1129. https://doi.org/10.1093/trstmh/trab048

82. Rogers Van Katwyk S, Jones SL, Hoffman SJ. Mapping educational opportunities for healthcare workers on antimicrobial resistance and stewardship around the world. Human Resources for Health. 2018;16:1-18. https://doi.org/10.1186/s12960-018-0270-3
83. Rolfe R, Kwobah C, Muro F, Ruwanpathirana A, Lyamuya F, Bodinayake C, Nagahawatte A, Piyasiri B, Sheng T, Bollinger J, et al. Barriers to implementing antimicrobial stewardship programs in three low- and middle-income country tertiary care settings: findings from a multi-site qualitative study. Antimicrob Resist Infect Control. 2021;10(1). https://doi.org/10.1186/s13756-021-00929-4
84. Rooney AM, Raphenya AR, Melano RG, Seah C, Yee NR, MacFadden DR, McArthur AG, Schneeberger PH, Coburn B. Performance characteristics of next-generation sequencing for antimicrobial resistance gene detection in genomes and metagenomes. https://doi.org/10.1101/2021.06.25.449921
85. Sandar WP, Saw S, Kumar AM, Camara BS, Sein MM. Wounds, antimicrobial resistance, and challenges of implementing a surveillance system in Myanmar: a mixed-methods study. Trop Med Infect Dis. 2021;6(2):80. https://doi.org/10.3390/tropicalmed6020080
86. Serpa PH, Deng X, Abdelghany M, Crawford E, Malcolm K, Caldera S, Fung M, McGeever A, Kalantar KL, Lyden A, et al. Metagenomic prediction of antimicrobial resistance in critically ill patients with lower respiratory tract infections. Genome Med. 2022;14(1). https://doi.org/10.1186/s13073-022-01072-4
87. Sichen L, Rui W, Yue Y, Xin L, Youbin C, Ze T, Hongfei C. Analysis of drug resistance in pulmonary tuberculosis patients with positive sputum tuberculosis culture in northeast China. Front Pharmacol. 2023;14. https://doi.org/10.3389/fphar.2023.1263726
88. Siltrakool B, Berrou I, Griffiths D, Alghamdi S. Antibiotics' use in Thailand: community pharmacists' knowledge, attitudes, and practices. Antibiotics. 2021;10(2):137. https://doi.org/10.3390/antibiotics10020137
89. Slayton RB, Toth D, Lee BY, Tanner W, Bartsch SM, Khader K, Wong K, Brown K, McKinnell JA, Ray W, et al. Vital signs: estimated effects of a coordinated approach for action to reduce antibiotic-resistant infections in health care facilities—United States. Am J Transplant. 2015;15(11):3002-3007.
90. Song WM, Li YF, Ma XB, Liu JY, Tao NN, Liu Y, Zhang QY, Xu TT, Li SJ, Yu CB, et al. Primary drug resistance of Mycobacterium tuberculosis in Shandong, China, 2004–2018. Respir Res. 2019;20(1). https://doi.org/10.1186/s12931-019-1199-3
91. Spika J, Rud EW. Immunization as a tool to combat antimicrobial resistance. Can Commun Dis Rep. 2015;41(S5):7-10. https://doi.org/10.14745/ccdr.v41is5a02
92. Street TL, Sanderson ND, Kolenda C, Kavanagh J, Pickford H, Hoosdally S, Cregan J, Taunt C, Jones E, Oakley S, et al. Clinical metagenomic sequencing for species identification and antimicrobial resistance prediction in orthopedic device infection. J Clin Microbiol. 2022;60(4). https://doi.org/10.1128/jcm.02156-21
93. Tagliaferri TL, Guimarães NR, Pereira MDP, Vilela LFF, Horz HP, Dos Santos SG, Mendes TA. Exploring the potential of CRISPR-Cas9 under challenging conditions: facing high-copy plasmids and counteracting beta-lactam resistance in clinical strains of Enterobacteriaceae. Front Microbiol. 2020;11. https://doi.org/10.3389/fmicb.2020.00578
94. Trick AY, Melendez JH, Chen FE, Chen L, Onzia A, Zawedde A, Nakku-Joloba E, Kyambadde P, Mande E, Matovu J, et al. A portable magnetofluidic platform for detecting sexually transmitted infections and antimicrobial susceptibility. Sci Transl Med. 2021;13(593). https://doi.org/10.1126/scitranslmed.abf6356
95. Truppa C, Alonso B, Clezy K, Deglise C, Dromer C, Garelli S, Jimenez C, Kanapathipillai R, Khalife M, Repetto E. Antimicrobial stewardship in primary health care programs in humanitarian settings: the time to act is now. Antimicrob Resist Infect Control. 2023;12(1). https://doi.org/10.1186/s13756-023-01301-4
96. Upadhaya S, Acharya J, Zolfo M, Nair D, Kharel M, Shrestha A, Shrestha B, Madhup SK, Raghubanshi BR, Kattel HP, et al. Has data quality of an antimicrobial resistance surveillance system in a province of Nepal improved between 2019 and 2022? Trop Med Infect Dis. 2023;8(8):399. https://doi.org/10.3390/tropicalmed8080399
97. Uribe RV, Rathmer C, Jahn LJ, Ellabaan MMH, Li SS, Sommer MOA. Bacterial resistance to CRISPR-Cas antimicrobials. Sci Rep. 2021;11(1):17267. https://doi.org/10.1038/s41598-021-96735-4
98. Valencia C, Hammami N, Agodi A, Lepape A, Herrejon EP, Blot S, Vincent JL, Lambert ML. Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey. Antimicrob Resist Infect Control. 2016;5(1). https://doi.org/10.1186/s13756-016-0139-y
99. Viale P, Giannella M, Bartoletti M, Tedeschi S, Lewis R. Considerations about antimicrobial stewardship in settings with epidemic extended-spectrum β-lactamase-producing or carbapenem-resistant Enterobacteriaceae. Infect Dis Ther. 2015;4(S1):65-83. https://doi.org/10.1007/s40121-015-0081-y

100. Walia K, Madhumathi J, Veeraraghavan B, Chakrabarti A, Kapil A, Ray P, et al. Establishing antimicrobial resistance surveillance & research network in India: journey so far. Indian J Med Res. 2019;149(2):164. https://doi.org/10.4103/ijmr.ijmr_226_18
101. Walker-Sünderhauf D, Klümper U, Pursey E, Westra ER, Gaze WH, van Houte S. Removal of AMR plasmids using a mobile, broad host-range CRISPR-Cas9 delivery tool. Microbiology. 2023;169(5). https://doi.org/10.1099/mic.0.001334
102. Wongpayak P, Meesungnoen O, Saejang S, Subsoontorn P. A highly effective and self-transmissible CRISPR antimicrobial for elimination of target plasmids without antibiotic selection. PeerJ. 2021;9
103. Wu Y, Battalapalli D, Hakeem MJ, Selamneni V, Zhang P, Draz MS, Ruan Z. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnol. 2021;19(1). https://doi.org/10.1186/s12951-021-01132-8